Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients
Enabling wireless monitoring In ambulances and homes
It provides doctors with three indicators: identification of the bone, confirmation of device insertion into the bone, and notification in case of perforation through the opposite end of the bone
FedEx will be displaying a wide-range of effective healthcare packaging and specialized tracking technology
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
Amala Hospital partners with LifeSigns to provide revolutionary technology for the first time in the State
Azelis’ customers now have access to products including the well-established Polyglykol portfolio, as well as a brand-new range of Motusflex and VitiPure excipients.
Aimed at improving patient outcomes and increasing connectivity for more efficient monitoring In hospitals and homes
Her appointment further strengthens the CDMO’s strategy to become the nutraceutical R&D hub for brands looking for agile partners with large scientific and development resources
Subscribe To Our Newsletter & Stay Updated